Cancer Pipeline Valuation: VEGF Trap (Regeneron) – A Deal Worth more than 500M USD?
Cancer Pipeline Valuation: VEGF Trap (Regeneron) – A Deal Worth more than 500M USD?
(PRWEB) January 29, 2004
BioSeeker Group AB (Stockholm, Sweden)– The VEGF (Vascular Endothelial Growth Factor) Trap is a composite decoy receptor fusion protein that contains portions of the extracellular domains of two different VEGF receptors VEGFR-1 (flt-1) and VEGFR-2 (KDR). The VEGF Trap (R1R2) has a high affinity for VEGF.
In September 2003, Aventis and Regeneron Pharmaceuticals initiated a global agreement (excluding Japan) according to which the companies will together develop and commercialize VEGF Trap. This is a deal with a value of more than 500M USD. Is the actual value of the early stage candidate in this magnitude? In a new business report, BioSeeker Group assesses VEGF Trap and gives you an independent and unbiased valuation.
The progress in utilizing biological strategies to inhibit vascular endothelial growth factor receptor (VEGF/VEGFR) signal transduction for the treatment of cancer is described. Additionally, small molecular inhibitor candidates of the VEGFR tyrosine kinase are presented.
In this specific valuation we have chosen to closely study a biological drug with anti-angiogenetic property, utilizing a relative new approach of targeting VEGF. Regeneron’s VEGF Trap has been studied in detail and this report reviews this the possibilities and opportunities of this candidate as well as the competition and drawbacks for targeting the VEGF/VEGFR signal transduction pathway. BioSeeker Group has identified a total of 114 different therapies developed utilizing an antiangiogenetic or vascular targeting strategy. The progress of 22 different therapeutic candidates that have a VEGF/VEGFR signal transduction inhibitory effect are also described. For your convenience, data is summarized in tables and graphs to enhance the overall view of this field.
BioSeeker Group is an independent, privately owned company based in Sweden. We focus on business, competitive intelligence in biotech and life science and operate in two business areas: consulting and publishing. Our mission is to excel our customer’s business operations by objective and unbiased research and analysis.
http://www.BioSeeker.com
©Copyright 1997-
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Related posts:
- Oral Cancer Kills Someone in the United States Every Hour of Every Day: Delta Dental Encourages Americans to Request Oral Cancer Exams from Dentists in Recognition of National Oral Cancer Awareness Week (April 16-22)
- What is a MuzzleMat? Only the Best Accessory Any Skeet Or Trap Shooter Should Own
- Building a Simple Shed Trap
- Unemployed? Report Reveals The Job Hunting Mistakes That Keep You Out of Work
- Clay Pigeon Thrower – Build One Yourself